BioArctic AB (publ) (STO: BIOA.B)
Sweden
· Delayed Price · Currency is SEK
166.50
-7.30 (-4.20%)
Aug 30, 2024, 5:29 PM CET
BioArctic AB Revenue
BioArctic AB had revenue of 50.40M SEK in the quarter ending June 30, 2024, with 1,736.17% growth. This brings the company's revenue in the last twelve months to 301.85M, down -51.08% year-over-year. In the year 2023, BioArctic AB had annual revenue of 616.00M with 168.49% growth.
Revenue (ttm)
301.85M
Revenue Growth
-51.08%
P/S Ratio
48.65
Revenue / Employee
3.35M
Employees
88
Market Cap
14.71B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
Dec 31, 2019 | 282.94M | -439.28M | -60.82% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 1, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 520.76B |
Swedish Orphan Biovitrum AB (publ) | 23.71B |
Getinge AB (publ) | 33.33B |
Sectra AB (publ) | 3.04B |
Camurus AB (publ) | 1.59B |
Vitrolife AB (publ) | 3.54B |
Medicover AB (publ) | 21.70B |
Elekta AB (publ) | 18.12B |
BioArctic AB News
- 6 days ago - Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology - PRNewsWire
- 10 days ago - Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain - PRNewsWire
- 11 days ago - Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic - PRNewsWire
- 14 days ago - Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET - PRNewsWire
- 19 days ago - Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates - PRNewsWire
- 4 weeks ago - Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024 - PRNewsWire
- 4 weeks ago - Long-term lecanemab data show increased patient benefit with maintained safety profile - PRNewsWire
- 5 weeks ago - Eisai will seek re-examination of CHMP opinion för lecanemab - PRNewsWire